GEN Exclusives

More »

GEN News Highlights

More »
Jun 7, 2011

EU Approves Biogen Idec’s Avonex Intramuscular Autoinjector Product for MS

  • The European regulatory authorities approved Biogen Idec’s single-use intramuscular autoinjector, Avonex PEN, for patients with relapsing multiple sclerosis and those who have had a single demyelinating event. The prefilled, once-a-week Avonex-based product integrates the previously approved Avonex prefilled syringe with a shorter needle.  

    Clearance in the EU was based on data from an open-label Phase IIIb study in which patients previously using the Avonex prefilled syringe were switched to the new Avonex PEN device. The overall success rate for patients using Avonex PEN was 89%, and 94% of patients expressed a preference for the device over the Avonex prefilled syringe.  


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »